Affymetrix Selects BioDiscovery as OncoScan™ FFPE Express Preferred Software Provider
27 May 2011 - 8:15PM
Business Wire
Affymetrix, Inc. (NASDAQ:AFFX) today announced a co-marketing
agreement naming BioDiscovery, Inc. its preferred software provider
for Affymetrix OncoScan™ FFPE Express Service data analysis.
BioDiscovery, a leader in integrated software for high-throughput
microarrays and other technologies, customized its Nexus Copy
Number™ solution for Affymetrix to make the most user-friendly,
flexible, and compatible tool available for OncoScan FFPE Express
microarray data analysis. Cancer researchers using the OncoScan
Service and Nexus software can now obtain critical cancer genome
measurements from archived formalin-fixed, paraffin-embedded (FFPE)
tumor samples and obtain an end-to-end solution for faster data
visualization and analysis.
“By simplifying data interpretation with the Nexus Copy Number
software, we’re providing a complete solution to our customers,”
said Nargol Faravashi, Affymetrix Global Strategic Marketing
Manager, DNA Cancer Applications. “Our array technology
accommodates challenging FFPE tumor samples as old as 28 years. Now
that it’s coupled with a best-in-class software solution for
visualizing the cancer genome at fine resolution, researchers have
a very powerful method to streamline their data analysis processes
and accelerate scientific discoveries.”
Under the co-marketing agreement, customers accessing the
OncoScan FFPE Express Service through the Affymetrix® Research
Services Laboratory (ARSL) will receive a preliminary Nexus Copy
Number data analysis. Additionally, BioDiscovery will provide a
one-on-one consultation session to assist each researcher with the
downstream analysis of their data to elucidate pathways and
identify copy number variations (CNV) and copy-neutral loss of
heterozygosity (LOH) events, which are important for understanding
characterizations of mutations.
“Pairing Nexus Copy Number software with Affymetrix’ unique
service is an ideal solution for a comprehensive workflow—from FFPE
samples to final analysis and visualization of CNV and LOH
results,” said BioDiscovery CEO Dr. Soheil Shams. “The latest 6.0
version of our Nexus Copy Number solution is well-designed to
analyze data generated from the OncoScan FFPE Express Service,
especially with the addition of custom tools for cancer sample
analysis.”
The OncoScan™ FFPE Express Service, based on Affymetrix’ unique
molecular inversion probe (MIP) array technology, was designed in
collaboration with leading cancer scientists. It overcomes the
challenge of analyzing DNA from FFPE tissues to extract important
retrospective clinical data from archived samples and goes beyond
the limitations of standard array comparative genomic hybridization
(CGH) methods to yield copy number, allelic ratio, and somatic
mutation data from minimal amounts of input DNA.
“Many leading cancer researchers are avid users of Nexus Copy
Number for its ease of use, robustness, and flexibility to suit
each individual’s needs,” added BioDiscovery CEO Dr. Shams. “Now,
customers of the OncoScan FFPE Express Service will receive not
only high-quality raw data from Affymetrix, but also reliable
analysis of experimental results that further streamline and speed
their research.”
BioDiscovery’s software is platform-independent and available
for Mac OS X, Linux, and Windows operating systems. In a single
project, Nexus Copy Number can integrate and process the data from
nearly all commercial array platforms, as well as custom arrays.
With free access to a web-based repository for querying and storing
genomic data from any location across the globe, Nexus Copy Number
is a powerful solution for large study groups and consortia. The
software is applicable to many types of studies, from focused
cytogenetic projects studying chromosome defects to large-scale
cancer or genome-wide association studies (GWAS).
About Affymetrix
Affymetrix technology is used by the world's top pharmaceutical,
diagnostic, and biotechnology companies, as well as leading
academic, government and nonprofit research institutes. More than
2,000 systems have been shipped around the world and more than
23,000 peer-reviewed papers have been published using the
technology. Affymetrix is headquartered in Santa Clara, Calif., and
has manufacturing facilities in Santa Clara, Cleveland, Ohio, and
Singapore. The company has about 900 employees worldwide and
maintains sales and distribution operations across Europe, Asia,
and Latin America. For more information about Affymetrix, please
visit http://www.affymetrix.com.
About BioDiscovery
BioDiscovery is a leader in the development of advanced
microarray bioinformatics software and services that enable its
customers to revolutionize drug discovery and diagnostics by
efficiently managing, integrating, and analyzing data generated
using high-throughput microarray technology. Contact BioDiscovery
at (310) 414-8100 or www.biodiscovery.com.
NOTE: Affymetrix, the Affymetrix logo, and OncoScan are
trademarks or registered trademarks of Affymetrix, Inc.; Nexus Copy
Number is a trademark or registered trademark of BioDiscovery,
Inc.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2023 to Aug 2024